-
1 Comment
Syncom Healthcare Limited is currently in a long term uptrend where the price is trading 58.3% above its 200 day moving average.
From a valuation standpoint, the stock is 47.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Syncom Healthcare Limited's total revenue sank by 52.8% to $5M since the same quarter in the previous year.
Its net income has dropped by 2.0% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 3528.6% to $30M since the same quarter in the previous year.
Based on the above factors, Syncom Healthcare Limited gets an overall score of 3/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| ISIN | INE602K01014 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| PE Ratio | None |
|---|---|
| Beta | 1.45 |
| Market Cap | 170M |
| Target Price | None |
| Dividend Yield | 0.0% |
Syncom Healthcare Limited engages in the manufacture and marketing of pharmaceutical formulations in India and internationally. It also offers nutraceutical products and ayurvedic formulations. The company was incorporated in 2002 and is based in Indore, India. Syncom Healthcare Limited is in corporate insolvency resolution process under the provisions of Section 7 of the Insolvency and Bankruptcy Code, 2016.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SYNCOM.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
